Design of oral sustain release drug delivery of quetiapine fumarate

Abstract

Oral administration of drugs has been the most common and preferred route for delivery of most effective agents. It occurs the prior route of administration investigated in the discovery and development of new drug candidates and formulations. The popularity of oral route is attributed to accurate dosing, ease of administration, cost effective manufacturing method, patient acceptances and generally improved shelf life of the product. In recent years, considerable attention has been focused on development of sustained release drug delivery systems. The rationale for the development of sustain release drug delivery system of a drug is to enhance its therapeutic advantages, reducing its side effects while improving the management of the diseased condition.¹⁵

Quetiapine fumarate is a dibenzothiazepine derivative, & a recent antipsychotic drug with an atypical neuropharmacological profile. It has the highest serotonin dopamine binding ratio, being the serotonin type 2. (5HT₂) receptor blocking effect about twice as strong as the dopamine D2-receptor blocking effect, thereby leaving more active neurotransmitter in the synapse. It is widely prescribed for the treatment of schizophrenia & bipolar disorder.

Quetiapine fumarate is a BCS class II (poorly soluble, highly permeable) drug. It has a plasma half life of 6±1h. & a bioavailability of 83% in 1.5 h. For such drug hydrophilic matrix systems are more suitable.^.25